Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Development and evaluation of a new IgM/IgG rapid diagnostic test for SARS-CoV-2

View ORCID ProfileP.J. Ducrest
doi: https://doi.org/10.1101/2020.10.09.20209866
P.J. Ducrest
1GaDia SA, Route de l’ile au bois 1A, 1870 Monthey, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for P.J. Ducrest
  • For correspondence: percevent.ducrest@gadia.net
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

There is an urgent need in rapid diagnostic test (RDT) to detect antibodies against SARS-CoV-2. We have developed a rapid and simple point-of-care lateral flow immunoassay (LFIA) detecting IgM and IgG against SARS-CoV-2 in 10 minutes. The aim of this study is to evaluate the diagnostic performance of this RDT. RT-PCR positive plasma samples (n=35) for SARS-CoV-2 and 97 negative control samples were studied. Diagnostic performance of IgG/IgM RDT was assessed using both gold standard RT-PCR and Electro-chemiluminescence immunoassay (ECLIA) Elecsys® Anti-SARS-CoV-2 total Ig. Overall, RDT sensitivity was 100% (95% confidence interval [95%CI]: 88-100%) and specificity 93% (95% CI: 85-97%). This IgG/IgM RDT done in plasma displays a high diagnostic accuracy for SARS-CoV-2 IgG/IgM in high COVID-19 prevalence settings. Its use could be considered in the absence of routine diagnostic serology facilities for samples collected between 10 and 180 days after symptoms onset.

Competing Interest Statement

PJD is the CEO of GaDia SA, the developer and manufacturer of this RDT.

Clinical Trial

This study was evaluated by the Ethics Committee (CER-VD) and they judged that it did not deserve a specific approval being only a quality assessment of diagnostic tests with foreign leftover samples.

Funding Statement

This study was funded by GaDia SA.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study was evaluated by the Ethics Committee (CER-VD) and they judged that it did not deserve a specific approval being only a quality assessment of diagnostic tests with foreign leftover samples. All necessary patient/participant consent has been obtained by the supplier of the samples.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Data available in Supplementary Material

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Back to top
PreviousNext
Posted October 13, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Development and evaluation of a new IgM/IgG rapid diagnostic test for SARS-CoV-2
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Development and evaluation of a new IgM/IgG rapid diagnostic test for SARS-CoV-2
P.J. Ducrest
medRxiv 2020.10.09.20209866; doi: https://doi.org/10.1101/2020.10.09.20209866
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Development and evaluation of a new IgM/IgG rapid diagnostic test for SARS-CoV-2
P.J. Ducrest
medRxiv 2020.10.09.20209866; doi: https://doi.org/10.1101/2020.10.09.20209866

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (62)
  • Allergy and Immunology (142)
  • Anesthesia (46)
  • Cardiovascular Medicine (415)
  • Dentistry and Oral Medicine (70)
  • Dermatology (47)
  • Emergency Medicine (144)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (171)
  • Epidemiology (4857)
  • Forensic Medicine (3)
  • Gastroenterology (183)
  • Genetic and Genomic Medicine (676)
  • Geriatric Medicine (70)
  • Health Economics (192)
  • Health Informatics (630)
  • Health Policy (320)
  • Health Systems and Quality Improvement (206)
  • Hematology (85)
  • HIV/AIDS (156)
  • Infectious Diseases (except HIV/AIDS) (5339)
  • Intensive Care and Critical Care Medicine (331)
  • Medical Education (93)
  • Medical Ethics (24)
  • Nephrology (75)
  • Neurology (686)
  • Nursing (42)
  • Nutrition (115)
  • Obstetrics and Gynecology (126)
  • Occupational and Environmental Health (208)
  • Oncology (439)
  • Ophthalmology (140)
  • Orthopedics (36)
  • Otolaryngology (89)
  • Pain Medicine (35)
  • Palliative Medicine (16)
  • Pathology (129)
  • Pediatrics (194)
  • Pharmacology and Therapeutics (131)
  • Primary Care Research (84)
  • Psychiatry and Clinical Psychology (780)
  • Public and Global Health (1816)
  • Radiology and Imaging (324)
  • Rehabilitation Medicine and Physical Therapy (138)
  • Respiratory Medicine (255)
  • Rheumatology (86)
  • Sexual and Reproductive Health (69)
  • Sports Medicine (62)
  • Surgery (100)
  • Toxicology (23)
  • Transplantation (29)
  • Urology (37)